Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Poxel Announces Participation at Several Upcoming Scientific and Investor Conferences

10/28/2020 | 08:23am EST

LYON - POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that members of the Poxel management and scientific team will participate at several upcoming scientific and investor conferences.

B. Riley Liver Disease Therapeutics Day

Date: October 29, 2020 (virtual event)

David E. Moller, MD, Executive Vice President and Chief Scientific Officer, will participant in a panel session to discuss Poxel's two NASH clinical-stage candidates, PXL770 and PXL065. PXL770 is a first-in-class, oral direct adenosine monophosphate-activated protein kinase (AMPK) activator. PXL065 is a novel, oral, proprietary deuterium-stabilized R-stereoisomer of pioglitazone.

DirectDirigeants Event

Date: November 3, 2020 (in-person conference)

Location: Paris

Thomas Kuhn, CEO of Poxel, will present a corporate update.

American Association for the Study of Liver Diseases (AASLD), The Liver Meeting

Date: November 13-16, 2020 (virtual)

Members of Poxel's scientific team will present three posters on PXL770 results and one poster on PXL065 results.

ALD Connect Annual Meeting

Date: November 13-14, 2020 (virtual)

Members of Poxel's scientific team will participate and present at this conference.

Bryan Garnier Healthcare Conference

Date: November 16, 2020 (virtual)

Members of the Poxel management team will be available for one-on-one virtual meetings.

Jefferies Virtual London Healthcare Conference

Date: November 17-19, 2020 (virtual); Poxel presentation: November 18th at 9:40-10:10 am EST / 2:40-3:10 pm GMT

Members of the Poxel management team will present a corporate overview and will be available for one-on-one virtual meetings. To access the webcast, please visit https://wsw.com/webcast/jeff141/poxel.pa/2381175. The webcast replay will remain available for 90 days following the live presentation.

Oddo Tech40 Digital Forum

Date: November 24-25, 2020 (virtual)

Members of the Poxel management team will be available for one-on-one virtual meetings.

About Poxel SA

Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel's first-in-class lead product, targets mitochondrial dysfunction. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. A Japanese new drug application (J-NDA) is under review by the Pharmaceuticals and Medical Devices Agency (PMDA) to request approval for the manufacturing and marketing of Imeglimin for the treatment of type 2 diabetes. Poxel also established a partnership with Roivant Sciences for Imeglimin's development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH. The Phase 2a trial met its primary endpoint and study objectives. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a MPC inhibitor, is in a single Phase 2 trial for the treatment of NASH. Poxel also has additional earlier-stage programs from its AMPK activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March 12, 2020, the Company is regularly reviewing the impact of the outbreak on its business.

As of the date of this press release, and based on publicly available information, the Company has not identified the occurrence of any material negative effect on its business due to the COVID-19 pandemic that remains unresolved. However, the Company anticipates that the COVID-19 pandemic could have further material negative impact on its business operations. The worldwide impact of COVID-19 may notably affect the Company's internal organization and efficiency, particularly in countries where it operates and where confinement measures are implemented by the authorities. In addition, COVID-19 may impact market conditions and the Company's ability to seek additional funding or enter into partnerships. Particularly, delays in the supply of drug substance or drug products, in the initiation or the timing of results of preclinical and/or clinical trials, as well as delays linked to the responsiveness of regulatory authorities could occur, which could potentially have an impact on the Company's development programs and partnered programs. The Company will continue to actively monitor the situation.

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'target,' 'believe,' 'expect,' 'aim,' 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.


Jonae R. Barnes

Tel: +1 617 818 2985

Email: jonae.barnes@poxelpharma.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
POXEL 0.90% 6.76 Real-time Quote.-44.59%
SUMITOMO CHEMICAL COMPANY, LIMITED -3.90% 370 End-of-day quote.-25.70%
SUMITOMO DAINIPPON PHARMA CO., LTD. -4.55% 1323 End-of-day quote.-37.89%
All news about POXEL
11/30POXEL : to Host Virtual NASH Investor Event with Leading Experts on December 14,..
11/23Poxel Provides Update on Metavant Partnership with Imeglimin
11/23POXEL : Corporate Presentation - English
11/20POXEL : Provides Update on Metavant Partnership with Imeglimin
11/17POXEL : Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data f..
11/16POXEL : Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data f..
11/10POXEL : Corporate Presentation - English
11/09POXEL : Announces Upcoming Poster Presentations at AASLD The Liver Meeting® 2020
10/28Poxel Announces Participation at Several Upcoming Scientific and Investor Con..
10/27POXEL : Announces Participation at Several Upcoming Scientific and Investor Conf..
More news
Sales 2020 7,93 M 9,49 M 9,49 M
Net income 2020 -30,7 M -36,7 M -36,7 M
Net cash 2020 11,0 M 13,2 M 13,2 M
P/E ratio 2020 -5,66x
Yield 2020 -
Capitalization 190 M 228 M 228 M
EV / Sales 2020 22,6x
EV / Sales 2021 4,46x
Nbr of Employees 51
Free-Float 75,3%
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Average target price 18,17 €
Last Close Price 6,70 €
Spread / Highest target 213%
Spread / Average Target 171%
Spread / Lowest Target 146%
EPS Revisions
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Sebastien Bolze Chief Operating Officer & Executive Vice President
Anne Renevot Chief Financial Officer & Executive Vice President
Sophie Hallakou-Bozec Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.56.53%38 135
BIONTECH SE266.71%29 915